Prof. Dr. med. Patrick Most

Study of Medicine (Medical Colleges of the University of
Heidelberg and University of Lübeck)
 

Medical Internship, University Hospital Lübeck

Full license to practice medicine (Approbation)

Resident, Department of Cardiology, Angiology and
Pulmonology, University Hospital Lübeck
 

Medical doctorate degree/thesis defense (summa cum laude)

Resident, Department of Cardiology, Angiology and
Pulmonology, University Hospital Heidelberg

Post-doctorate  training,  Center  for  Translational  Medicine,

Thomas Jefferson University, Philadelphia, USA

Assistant  Professor  of  Medicine  and  faculty  member  and,
Medical   College   and   Department   of   Medicine,   Thomas
Jefferson University Hospital, Philadelphia, USA
 

Board certification

W3-Professor  for  Molecular  and  Translational  Cardiology, Medical College and Heidelberg University Hospital, Heidelberg Germany

Adjunct Associate Professor of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, USA

Co-founder and Chief Executive Officer of the Biotech Startup
InoCard GmbH

Managing Director of uniQure GmbH Germany (successor to InoCard GmbH and German affiliation of uniQure NV, Amsterdam, Netherlands)

Member of the uniQure NV leadership team and Senior Vice
President Cardiovascular Therapeutic Area
 

Co-founder of the Biotech Startup AaviGen GmbH

German Society of Cardiology (DGK), of the Oskar Lapp
Foundation Science Award

Council on Basic Cardiovascular Sciences (BCVS) of the American Heart Association (AHA), Trainee Award

Council  on  Basic  Cardiovascular  Sciences  (BCVS)  of  the American Heart Association (AHA), Early Carrer Development Award

Young Investigator Award of the German Society for Internal Medicine (DGIM)
 

Wilhelm P. Winterstein Science Award of the German Heart

Foundation (Deutsche Herzstiftung) Basic Science Award of the German Society for the Prevention  and  Rehabilitation  of  Cardiovascular  Diseases (DGPR)
 

Council on Basic Cardiovascular Sciences (BCVS) of the American Heart Association (AHA), Louis N. and Arnold M. Katz Price Finalist

W.W. Smith Charitable Trust stipend award

Innovation Award of BioRegion Germany Association

ADUMED Science Award, ADUMED Foundation

Investors’ Choice Award  of the  Health Axis Europe/BioRN
Excellence cluster competition

German Society of Cardiology (DGK), Albert-Fränkel Award

• Cardiac power failure treatment (WO2000/02453)
• Therapeutic Window S100A1 (PCT/EP13/186913)
• Muscle function enhancing peptide (PCT/EP10/002343)
• Short peptides for enhancing muscle function (PCT/EP13/880705)
• Tissue specific gene therapy treatment (WO2008/054713)